Xbrane Biopharma Q1 2024: Approaching an eventful second half of the year

Research Update

2024-05-17

07:45

Redeye returns with a research update following Xbrane’s Q1 report. Sales and EBIT were lower than we had estimated, but end-customer sales grew 30%. The report prompts minor adjustments to our forecasts and valuation.

FE

Filip Einarsson

Analyst Q&A

Closed

Filip Einarsson answered 5 questions.

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.